Clinical trials
NMOSD clinical trials
Below are recruiting nmosd clinical trials, each written for real people, not researchers. We’re tracking 23 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05966467Recruiting
Patient registry for AQP4+ neuromyelitis optica on C5 inhibitors
This registry collects health and relapse information from adults with AQP4-positive NMOSD who are taking C5-blocking medicines to prevent long-term relapses. It helps researchers better understand treatment patterns and outcomes in real-world care.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07762872Recruiting
Satralizumab during early NMOSD attacks
This study looks at how well the medication satralizumab works when started early during an NMOSD attack, along with standard treatments. The aim is to see if adding this drug can help reduce the impact of the attack and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05199688RecruitingPhase 3
Satralizumab for children with AQP4-positive NMOSD attacks
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
Denver, ColoradoAges 2–11 - NCT06780709Recruiting
Wellness program for neuromyelitis optica patients
This trial tests a structured wellness program to improve quality of life for people with neuromyelitis optica (NMOSD). It is designed to be accessible for any level of disability.
New York, New YorkAges 18 years+ - NCT05145361RecruitingEarly Phase 1
Study drug B001 for neuromyelitis optic spectrum disorder attacks
This early-phase study tests B001 injection to see if it can help people with neuromyelitis optica spectrum disorder (NMOSD) who have had recent relapses. It may be aimed at reducing future attacks and improving disability over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05504694RecruitingPhase 1/Phase 2
Ofatumumab for AQP4-positive NMOSD with recent relapses
This trial studies ofatumumab to reduce disease activity in adults with AQP4-IgG positive NMOSD who have had recent relapses. It may help lower the chance of new attacks and help prevent worsening disability over time.
Xi'an, ShaanxiAges 18 years+ - NCT05566769Recruiting
Test a phone tool for self-checks in NMOSD
This study tests a digital (phone) tool that helps people with NMOSD do unsupervised self-assessments between clinic visits. It looks at how well the tool works and whether it is safe and understandable for patients.
Los Angeles, CaliforniaAges 18 years+ - NCT05909761Recruiting
Pregnancy Uplizna safety study in women with NMOSD
This is an observational study that looks at the safety of Uplizna (satralizumab) during pregnancy for women who have neuromyelitis optica spectrum disorder (NMOSD). You may be asked to share information because your exposure to Uplizna happened during pregnancy or just before conception.
Aurora, ColoradoAges 15 years+ - NCT06249438RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune diseases
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06312644Recruiting
Study of Ultomiris safety during pregnancy
This study looks at the safety of the medication Ultomiris when taken during pregnancy or breastfeeding. If you are pregnant and currently taking Ultomiris for an approved condition, this research will help gather information on how it affects you and your baby.
Boston, MassachusettsAges Any age - NCT06413654RecruitingPhase 2/Phase 3
B001 for NMOSD: reducing relapses
This trial tests an investigational drug called B001 for people with NMOSD who have had recent relapses. The goal is to see if it can reduce future flare-ups.
BeijingAges 18 years+ - NCT06697535RecruitingPhase 2
Study of JYP0061 for acute NMOSD attacks
This trial tests a new medication called JYP0061 for people with NMOSD who are currently experiencing a sudden worsening of symptoms (acute attack). It aims to see if the drug can help control the attack and improve outcomes.
Changsha, HunanAges 18–65 - NCT06775912RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune diseases
This trial tests a new CAR-T cell therapy that targets two proteins (CD19 and BCMA) on immune cells. It's designed for people with certain autoimmune diseases like lupus, scleroderma, vasculitis, myositis, or Sjögren's syndrome that are not controlled by standard treatments.
Lianyungang, JiangusAges 18–70 - NCT06885957Recruiting
Monoclonal antibodies for AQP4-positive NMOSD
This trial is testing monoclonal antibody treatments for people with a specific type of neuromyelitis optica spectrum disorder (NMOSD) caused by AQP4 antibodies. It aims to see if these targeted therapies can help control the disease and prevent relapses.
Wuhan, HubeiAges 18–65 - NCT06940323Recruiting
Pregnancy study for women with chronic conditions
This study tracks pregnant women with certain chronic health conditions (like multiple sclerosis, lupus, or rheumatoid arthritis) and healthy pregnant women as a comparison group. It aims to understand how these conditions and their treatments affect pregnancy, the baby, and breast milk.
San Francisco, CaliforniaAges 18–64 - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT07087873Recruiting
Testing brain stimulation for memory problems in inflammatory diseases
This trial tests if a gentle electrical current applied to the scalp can improve memory and thinking in people with certain inflammatory conditions that affect the brain and spinal cord.
Beijing, Beijing MunicipalityAges 18–60 - NCT07377305Recruiting
Brain stimulation for nerve pain in NMOSD
This trial tests a new, non-invasive brain stimulation method (tTIS) to treat chronic nerve pain in people with neuromyelitis optica spectrum disorder (NMOSD). It aims to see if this treatment is safe and can reduce pain without surgery or drugs.
Xi'an, ShaanxiAges 18–75 - NCT07410039RecruitingPhase 4
Acute treatment for neuromyelitis optica in real-world setting
This study looks at treatments for people with neuromyelitis optica spectrum disorder (NMOSD) who are having a sudden attack affecting their vision or spinal cord. It aims to find out which treatments work best in everyday practice.
BeijingAges 18–65 - NCT07420296RecruitingPhase 3
Modified zipper therapy for AQP4-positive neuromyelitis optica
This trial tests a new treatment called modified zipper therapy for people with neuromyelitis optica spectrum disorder (NMOSD) who have a specific antibody (AQP4-IgG) in their blood. It aims to stop a recent attack and improve recovery.
TianjinAges 18–80 - NCT07526493RecruitingPhase 1
QH103 Cell Therapy for Resistant Autoimmune Nerve and Brain Diseases
This Phase 1 trial tests whether QH103 cell injections can help patients with serious autoimmune diseases affecting nerves and the brain (like MS, NMOSD, myasthenia gravis, and others) that haven't responded well to standard treatments. The goal is to evaluate safety and whether the treatment helps reduce symptoms.
Wuhan, HubeiAges 18–75 - NCT07653984Recruiting
Study on immune diseases in women of childbearing age
This study follows women with certain immune disorders affecting the nervous system (like multiple sclerosis or myasthenia gravis) to understand how these conditions affect reproduction. Healthy women planning pregnancy are also included for comparison.
Guangzhou, GuangdongAges 20–55 - NCT04886492Enrolling by invitation
NMOSD patient registry to help study future treatments
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
Waltham, MassachusettsAges 18 years+
Hear when a new NMOSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nmosd?
- Yes. Clin2 currently lists 23 recruiting nmosd studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nmosd trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nmosd trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.